1,406 results match your criteria: "and University of Pittsburgh[Affiliation]"
Front Antibiot
May 2024
Division of Emergency Medicine, Boston Children's Hospital and Harvard Medical School, Boston, MA, United States.
Background: The 2018 Infectious Disease Committee of the American Academy of Pediatrics stated that up to 3 weeks or less of doxycycline is safe in children of all ages. Our goal was to examine trends in doxycycline treatment for children with Lyme disease.
Methods: We assembled a prospective cohort of children aged 1 to 21 years with Lyme disease who presented to one of eight participating Pedi Lyme Net centers between 2015 and 2023.
N Engl J Med
January 2025
From the National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation (C.E.G., E.P.M., N.W., P.R., I.L.W., A.M.B.) and University of Pittsburgh School of Medicine-UPMC Hillman Cancer Center (C.E.G., N.W., P.R., A.M.B.) - both in Pittsburgh; AGO-B and Helios Klinikum Berlin-Buch, Berlin (M.U.), the National Center for Tumor Diseases, Heidelberg University Hospital, and German Cancer Research Center, Heidelberg (A.S.), Evangelische Kliniken Gelsenkirchen, Gelsenkirchen (H.H.F.), Arbeitsgemeinschaft Gynäkologische Onkologie-Breast and Sana Klinikum Offenbach, Offenbach (C.J.), the Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen (P.A.F.), German Breast Group, Neu-Isenburg (P.W., S.L.), and the Center for Hematology and Oncology Bethanien, Goethe University, Frankfurt (S.L.) - all in Germany; National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (C.-S.H.); Instituto do Câncer do Estado de São Paulo, São Paulo (M.S.M.); Orlando Health Cancer Institute, Orlando, FL (E.P.M.); Hospital Universitario La Paz-Instituto de Investigación del Hospital Universitario La Paz, Madrid (A.R.); L'Institut du Cancer de Montpellier-Val d'Aurelle, Montpellier (V.D.), Institut Bergonié, INSERM Unité 1312, and Université de Bordeaux UFR Sciences Médicales, Bordeaux (H.R.B.) - all in France; Providence Cancer Institute, Portland, OR (A.K.C.); the Department of Surgery, Oncology, and Gastroenterology, University of Padua, and Oncology 2, Istituto Oncologico Veneto IRCCS, Padua (V.G.), and the Cancer Center Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo (E.R.C.) - all in Italy; Stanford University School of Medicine, Stanford, CA (I.L.W.); the National Cancer Institute, Mexico City (C.A.-S.); Yale University School of Medicine, Yale Cancer Center, and Smilow Cancer Hospital, New Haven, CT (M.P.D.); the All-Ireland Cooperative Oncology Research Group (J.P.C.), and the Oncology Unit, Cancer Clinical Trials and Research Unit, Beaumont RCSI Cancer Centre, and Cancer Trials Ireland (B.T.H.) - all in Dublin; Fudan University Shanghai Cancer Center, Shanghai, China (Z.S.); Institute for Oncology and Radiology of Serbia, Belgrade (L.S.); Grupo Médico Ángeles, Guatemala City, Guatemala (H.C.-S.); Roche Products, Welwyn Garden City, United Kingdom (A.K., A.S.); and F. Hoffmann-La Roche, Basel, Switzerland (C.L., T.B., B.N., E.R.).
Background: Patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer with residual invasive disease after neoadjuvant systemic therapy have a high risk of recurrence and death. The primary analysis of KATHERINE, a phase 3, open-label trial, showed that the risk of invasive breast cancer or death was 50% lower with adjuvant trastuzumab emtansine (T-DM1) than with trastuzumab alone.
Methods: We randomly assigned patients with HER2-positive early breast cancer with residual invasive disease in the breast or axilla after neoadjuvant systemic treatment with taxane-based chemotherapy and trastuzumab to receive T-DM1 or trastuzumab for 14 cycles.
EBioMedicine
December 2024
Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. Electronic address:
Background: There are important inter-relationships between miRNAs and metabolites: alterations in miRNA expression can be induced by various metabolic stimuli, and miRNAs play a regulatory role in numerous cellular processes, impacting metabolism. While both specific miRNAs and metabolites have been identified for their role in childhood asthma, there has been no global assessment of the combined effect of miRNAs and the metabolome in childhood asthma.
Methods: We performed miRNAome-metabolome-wide association studies ('miR-metabo-WAS') in two childhood cohorts of asthma to evaluate the contemporaneous and persistent miRNA-metabolite associations: 1) Genetic Epidemiology of Asthma in Costa Rica Study (GACRS) (N = 1121); 2) the Childhood Asthma Management Program (CAMP) (N = 312 and N = 454).
J Clin Invest
December 2024
Hillman Cancer Center, University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, USA.
Kirsten rat sarcoma viral oncogene homolog (KRAS) is the most frequently mutated oncogene in lung adenocarcinoma, with G12C and G12V being the most predominant forms. Recent breakthroughs in KRASG12C inhibitors have transformed the clinical management of patients with the G12C mutation and advanced our understanding of the function of this mutation. However, little is known about the targeted disruption of KRASG12V, partly due to a lack of specific inhibitors.
View Article and Find Full Text PDFRes Sq
December 2024
Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
First-line immune checkpoint inhibitor (ICI) combinations show responses in subsets of hepatocellular carcinoma (HCC) patients. Nearly half of HCCs are Wnt-active with mutations in (encoding for β-catenin), , or , and demonstrate limited benefit to ICI due to an immune excluded tumor microenvironment. We show significant tumor responses in multiple β-catenin-mutated immunocompetent HCC models to a novel siRNA encapsulated in lipid nanoparticle targeting (LNP-CTNNB1).
View Article and Find Full Text PDFSports Health
December 2024
University of Pittsburgh Medical Center Sports Medicine Concussion Program, Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania.
Background: Factors associated with performance outside of a normative range on dynamic exertion test (EXiT) after sport-related concussion (SRC) remain unknown. This study examined the role of demographic and medical history factors on performance using minimal detectable change (MDC) cutoff scores in athletes being cleared to return to sport (RTS) from SRC.
Hypothesis: Older age, being female, and body mass index (BMI) ≥50th percentile would be associated with worse EXiT performance and with increased likelihood of falling outside the normative MDC score range.
J Clin Oncol
December 2024
Margarita L. Zuley, MD, FACR, University of Pittsburgh, School of Medicine, and University of Pittsburgh Medical Center, Department of Radiology, Division of Breast Imaging, Pittsburgh, PA; Andriy I. Bandos, PhD, University of Pittsburgh, Graduate School of Public Health, Biostatistics, Pittsburgh, PA; Stephen W. Duffy, PhD, Queen Mary University of London, Wolfson Institute of Population Health, London GB-ENG; Durwin Logue, BS, University of Pittsburgh, School of Medicine, Department of Radiology, Imaging Research, Pittsburgh, PA; Rohit Bhargava, MD, University of Pittsburgh, School of Medicine, Department of Pathology, and Pathology at Magee-Womens Hospital of the University of Pittsburgh Medical Center, Pittsburgh, PA; Priscilla F. McAuliffe, MD, PhD, FACS, University of Pittsburgh, School of Medicine, Department of Surgery, and Breast Surgical Oncology at Magee-Womens Hospital of the University of Pittsburgh Medical Center, Pittsburgh, PA; Adam M. Brufsky, MD, PhD, University of Pittsburgh, School of Medicine, Department of Surgery, and Breast Surgical Oncology at Magee-Womens Hospital of the University of Pittsburgh Medical Center, University of Pittsburgh, School of Medicine, and University of Pittsburgh Medical Center, Division of Hematology/Oncology, Pittsburgh, PA; and Robert M. Nishikawa, PhD, University of Pittsburgh, School of Medicine, Department of Radiology, Imaging Research, Pittsburgh, PA.
Nat Rev Gastroenterol Hepatol
December 2024
Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Hepatocellular carcinoma (HCC) represents a global health challenge, and ranks among one of the most prevalent and deadliest cancers worldwide. Therapeutic advances have expanded the treatment armamentarium for patients with advanced HCC, but obstacles remain. Precision oncology, which aims to match specific therapies to patients who have tumours with particular features, holds great promise.
View Article and Find Full Text PDFAm J Physiol Lung Cell Mol Physiol
January 2025
Center for Pulmonary Vascular Biology and Medicine, Pittsburgh Heart, Lung, and Blood Vascular Medicine Institute, Division of Cardiology, Department of Medicine, University of Pittsburgh School of Medicine and University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States.
JHEP Rep
December 2024
Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Background & Aims: Patients with β-catenin (encoded by )-mutated hepatocellular carcinoma (HCC) demonstrate heterogenous responses to first-line immune checkpoint inhibitors (ICIs). Precision-medicine based treatments for this subclass are currently in clinical development. Here, we report derivation of the Mutated β-catenin Gene Signature (MBGS) to predict -mutational status in patients with HCC for future application in personalized medicine treatment regimens.
View Article and Find Full Text PDFmedRxiv
October 2024
Center for Pulmonary Vascular Biology and Medicine, Pittsburgh Heart, Lung, and Blood Vascular Medicine Institute, University of Pittsburgh School of Medicine and University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA.
causes anthrax through a combination of bacterial infection and toxemia. As a major virulence factor of , anthrax lethal toxin (LT) is a zinc-dependent metalloproteinase, exerting its cytotoxicity through proteolytic cleavage of the mitogen-activated protein kinase kinases, thereby shutting down the MAPK pathways. Anthrax lethal toxin induces host lethality mostly by targeting the cardiovascular system.
View Article and Find Full Text PDFArthritis Care Res (Hoboken)
October 2024
British Columbia Children's Hospital, Vancouver, British Columbia, Canada.
Am J Obstet Gynecol MFM
December 2024
Department of Obstetrics and Gynecology and Center for Women's Reproductive Health, University of Alabama at Birmingham (Tita), Birmingham , Alabama, USA.
J Pediatric Infect Dis Soc
October 2024
Seattle Children's Research Institute, Seattle, WA.
Background: Previous investigations into clinical signs and symptoms associated with influenza types and subtypes have not definitively established differences in the clinical presentation or severity of influenza disease.
Methods: The study population included children 0 through 17 years old enrolled at 8 New Vaccine Surveillance Network sites between 2015 and 2020 who tested positive for influenza virus by molecular testing. Demographic and clinical data were collected for study participants via parent/guardian interview and medical chart review.
Pediatr Neurol
December 2024
Division of Child Neurology, UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania.
Background: This study aims to understand diagnosis communication experiences and preferences of youths with functional seizures and their parents.
Methods: Semistructured interviews with youths and their parents from a tertiary care children's hospital were conducted separately. We confirmed the diagnosis of functional seizures with the youth's treating providers.
bioRxiv
September 2024
Center for Pulmonary Vascular Biology and Medicine, Pittsburgh Heart, Lung, Blood, and Vascular Medicine Institute, Division of Cardiology, Department of Medicine, University of Pittsburgh School of Medicine and University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Pulmonary arterial hypertension (PAH) is a progressive disease driven by endothelial cell inflammation and dysfunction, resulting in the pathological remodeling of the pulmonary vasculature. Innate immune activation has been linked to PAH development; however, the regulation, propagation, and reversibility of the induction of inflammation in PAH is poorly understood. Here, we demonstrate a role for interferon inducible protein 16 (IFI16), an innate immune sensor, as a modulator of endothelial inflammation in pulmonary hypertension, utilizing human pulmonary artery endothelial cells (PAECs).
View Article and Find Full Text PDFNat Metab
October 2024
Department of Pathology and Translational Pathobiology, Louisiana State University Health Sciences Center-Shreveport, Shreveport, LA, USA.
The incidence of metabolic dysfunction-associated steatohepatitis (MASH) is on the rise, and with limited pharmacological therapy available, identification of new metabolic targets is urgently needed. Oxalate is a terminal metabolite produced from glyoxylate by hepatic lactate dehydrogenase (LDHA). The liver-specific alanine-glyoxylate aminotransferase (AGXT) detoxifies glyoxylate, preventing oxalate accumulation.
View Article and Find Full Text PDFAm J Pathol
September 2024
Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; Pittsburgh Liver Research Center, University of Pittsburgh Medical Center and University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. Electronic address:
Cholestasis, characterized by impaired bile flow, is associated with an increased risk of cholangiocarcinoma (CCA), a malignancy originating from the biliary epithelium and hepatocytes. Hepatic nuclear receptors (NRs) are pivotal in regulating bile acid and metabolic homeostasis, and their dysregulation is implicated in cholestatic liver diseases and the progression of liver cancer. This review elucidates the role of various hepatic NRs in the pathogenesis of cholestasis-to-CCA progression.
View Article and Find Full Text PDFArch Pathol Lab Med
September 2024
Sysmex America, Inc, Lincolnshire, Illinois (de Baca).
Am J Obstet Gynecol
September 2024
Department of Obstetrics and Gynecology, Center for Women's Reproductive Health, University of Alabama at Birmingham, Birmingham, AL.
Background: The Chronic Hypertension and Pregnancy Study demonstrated that a target blood pressure of <140/90 mm Hg during pregnancy is associated with improved perinatal outcomes. Outside of pregnancy, pharmacologic therapy for patients with diabetes and hypertension is adjusted to a target blood pressure of <130/80 mm Hg. During pregnancy, patients with both diabetes and chronic hypertension may also benefit from tighter control with a target blood pressure <130/80 mm Hg.
View Article and Find Full Text PDFJ Cell Biol
November 2024
Department of System Biology, School of Life Sciences, Guangdong Provincial Key Laboratory of Cell Microenvironment and Disease Research, Shenzhen Key Laboratory of Cell Microenvironment, Southern University of Science and Technology, Shenzhen, China.
Autophagy plays a crucial role in cancer cell survival by facilitating the elimination of detrimental cellular components and the recycling of nutrients. Understanding the molecular regulation of autophagy is critical for developing interventional approaches for cancer therapy. In this study, we report that migfilin, a focal adhesion protein, plays a novel role in promoting autophagy by increasing autophagosome-lysosome fusion.
View Article and Find Full Text PDFObstet Gynecol
October 2024
Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, Alabama, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, University of Pennsylvania, Philadelphia, Pennsylvania, University of Texas at Houston, Houston, Texas, Columbia University, New York, New York, Duke University, Durham, North Carolina, St. Luke's University Health Network, Bethlehem, Pennsylvania, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas, Metro Health/Case Western University, Cleveland, Ohio, Indiana University, Indianapolis, Indiana, Drexel University College of Medicine, Philadelphia, Pennsylvania, University of Utah Health, Salt Lake City, Utah, University of Texas Southwestern, Dallas, Texas, Intermountain Healthcare, Salt Lake City, Utah, Ochsner Health, New Orleans, Louisiana, University of Texas Medical Branch, Galveston, Texas, St. Peters University Hospital, New Brunswick, New Jersey, Washington University in St. Louis, St. Louis, Missouri, University of Mississippi Medical Center, Jackson, Mississippi, Magee Women's Hospital and University of Pittsburgh, Pittsburgh, Pennsylvania, The Ohio State University, Columbus, Ohio, Rutgers University-Robert Wood Johnson Medical School, Brunswick, New Jersey, Medical College of Wisconsin, Milwaukee, Wisconsin, University of South Alabama at Mobile, Mobile, Alabama, Weill Cornell University, New York City, New York, Yale University, New Haven, Connecticut, NYU Langone Hospital-Long Island, Mineola, New York, University of Colorado, Aurora, Colorado, Emory University, Atlanta, Georgia, Denver Health, Denver, Colorado, University of California, San Francisco, San Francisco, California, NewYork-Presbyterian Queens Hospital, Flushing, New York, Stanford University, Stanford, California, Arrowhead Regional Medical Center, Colton, California, Tulane University, New Orleans, Louisiana, Wright State University and Miami Valley Hospital, Dayton, Ohio, University of Kansas Medical Center, Kansas City, Kansas, Medical University of South Carolina, Charleston, South Carolina, Vanderbilt University School of Medicine, Nashville, Tennessee, and Tufts University School of Medicine, Boston, Massachusetts; Beaumont Hospital, Grand Rapids, Michigan; the Center for Women's Reproductive Health, the Department of Biostatistics, the Department of Pediatrics, and the Department of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama; the Christiana Care Center for Women's and Children Health Research, Newark, Delaware; Zuckerberg San Francisco General Hospital, San Francisco, California; the Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, Maryland; Virtua Health, Marlton, New Jersey; Oregon Health and Science University, Portland, Oregon; the Department of Obstetrics, University of Arkansas for Medical Sciences, Little Rock, Arkansas; the Fetal Care Center of Cincinnati, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Good Samaritan Hospital, Cincinnati, Ohio; the Department of Obstetrics, Gynecology and Women's Health, New Jersey Medical School, Rutgers Biomedical and Health Sciences, Newark, New Jersey; Obstetrics and Gynecology/Maternal-Fetal Medicine, University of Tennessee Health Science Center, Memphis, Tennessee; the Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Lehigh Valley Health Network, Allentown, Pennsylvania; and Obstetrics and Gynecology and Women's Health Institute, Cleveland Clinic, Cleveland, Ohio.
Objective: To compare differences in postpartum blood pressure (BP) control (BP below 140/90 mm Hg) for participants with hypertension randomized to receive antihypertensive treatment compared with no treatment during pregnancy.
Methods: This study was a planned secondary analysis of a multicenter, open-label, randomized controlled trial (The CHAP [Chronic Hypertension and Pregnancy] trial). Pregnant participants with mild chronic hypertension (BP below 160/105 mm Hg) were randomized into two groups: active (antihypertensive treatment) or control (no treatment unless severe hypertension, BP 160/105 mm Hg or higher).
J Natl Cancer Inst
January 2025
Department of Surgical Oncology, NSABP Foundation, Inc, UPMC Hillman Cancer Center, and University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Background: NRG Oncology NSABP B-39/RTOG 0413 compared whole-breast irradiation (WBI) to accelerated partial-breast irradiation (APBI). APBI was not equivalent to WBI in local tumor control. Secondary outcome was quality of life (QOL).
View Article and Find Full Text PDFActuators
June 2024
Department of Physical Medicine and Rehabilitation, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.
Despite advances in wearable robots across various fields, there is no consensus definition or design framework for the application of this technology in rehabilitation or musculoskeletal (MSK) injury prevention. This paper aims to define wearable robots and explore their applications and challenges for military rehabilitation and force protection for MSK injury prevention. We conducted a modified Delphi method, including a steering group and 14 panelists with 10+ years of expertise in wearable robots.
View Article and Find Full Text PDF